CSLCSLLY -0.30%73 Return-on-Tangible-Asset is 3.49% as of Dec. 2025, which is 79% below its 10-year median of 16.73. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $51.03 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,418 Biotechnology companies, CSL ranks better than 82.72% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. CSL's annualizedNet Income for the quarter that ended in Dec. 2025 was $802 Mil. CSL's average total tangible assets for the quarter that ended in Dec. 2025 was $23,009 Mil. Therefore, CSL's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 3.49%.
The historical rank and industry rank for CSL's Return-on-Tangible-Asset or its related term are showing as below:
CSLLY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.72 Med: 16.73 Max: 20.93
Current: 1.72
During the past 13 years, CSL's highest Return-on-Tangible-Asset was 20.93%. The lowest was 1.72%. And the median was 16.73%.
CSLLY's Return-on-Tangible-Asset is ranked better than 82.72% of 1418
companies
in the Biotechnology industry
Industry Median: -35.915
vs CSLLY: 1.72
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
CSL Return-on-Tangible-Asset Related Terms
CSL Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for CSL's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, CSL's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where CSL's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 3.49% mean?
CSL (CSLLY) has a Return-on-Tangible-Asset of 3.49% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on CSL and its competitors. This is 79% below median its historical median of 16.73. Over the past decade, CSL's Return-on-Tangible-Asset has ranged from 1.72 to 20.93. According to the industry distribution chart, CSL ranks #245 out of 1418 companies in the Biotechnology industry, placing it in the top 17.3%.
Is CSL's Return-on-Tangible-Asset too high?
CSL's current Return-on-Tangible-Asset of 3.49% is 79% below median its 10-year median of 16.73. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 20.93. Based on the distribution chart, CSL ranks #245 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #245 out of 1418 companies for Return-on-Tangible-Asset. This places CSL in the top 17% of its industry — outperforming the majority of peers. Historically, CSL's own Return-on-Tangible-Asset has ranged from 1.72 to 20.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on CSL and its competitors. CSL's current Return-on-Tangible-Asset is 3.49%, which is 79% below median its own 10-year median of 16.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.03, compared to a current price of $20.06 — trading 60.7% below its estimated fair value. The current Return-on-Tangible-Asset is 3.49%, which is 79% below median its 10-year median of 16.73. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For CSL (CSLLY), the current Return-on-Tangible-Asset is 3.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $20.06 is trading 60.7% below its estimated GF Value™ of $51.03.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Return-on-Tangible-Asset: 3.49% (79% below median its 10-year median of 16.73)
GF Value™: $51.03 vs. price of $20.06 (60.7% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
